Involvement of MIR-199a in cisplatin resistance of ovarian cancer cell through modulating expression of mTOR

National Medical Journal of China

Volumn 95, Issue 33, 2015, Pages 2705-2708

  Wang, Zhongxian ^a   Liu, Qiong ^a   Gao, Qiaoling ^a   Luo, Youzhen ^a   Li, Qian ^a   Chen, Jianling ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Chemotherapy; Drug resistance; MicroRNA; MTOR; Ovarian cancer

Indexed keywords

CISPLATIN; LIPOFECTAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 199A; UNCLASSIFIED DRUG; LUCIFERASE; MIRN199 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; DRUG MECHANISM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; WESTERN BLOTTING; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; OVARY TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; MICRORNAS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84943180156     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2015.33.013     Document Type: Article

References (12)

1. Shen J, Hung MC. Signaling-mediated regulation of MicroRNA processing[J]. Cancer Res, 2015, 75 (5): 783-791.
2. ∗ regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2) [J]. J Biol Chem, 2008, 283 (26): 18158-18166.
3. Ergun S, Tayeb TS, Arslan A, et al. The investigation of miR- 221-3p and PAK1 gene expressions in breast cancer cell lines[J]. Gene, 2015, 555 (2): 377-381.
4. Park EY, Chang E, Lee E.J., et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer sternness and chemoresistance [J]. Cancer Res, 2014, 74 (24): 7573-7582.
5. Luo ML, Gong C, Chen C.H., et al. Prolyl isomerase Pinl acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer[J]. Cancer Res, 2014, 74 (13): 3603-3616.
6. Borralho PM, Kren BT, Castro R.E., et al. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells [J]. FEBS J, 2009, 276 (22): 6689-6700.
7. O'Brien NA, McDonald K, Tong L., et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT [J]. Clin Cancer Res, 2014, 20 (13): 3507-3520.
8. Zoncu R, Efeyan A, Sabatini DM. mTOR; from growth signal integration to cancer, diabetes and ageing [J]. Nat Rev Mol Cell Biol, 2011, 12 (1): 21-35.
9. Hay N. The Akt-mTOR tango and its relevance to cancer [J]. Cancer Cell, 2005, 8 (3): 179-183.
10. Hisamatsu T, Mabuchi S, Matsumoto Y., et al. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary [J]. Mol Cancer Ther, 2013, 12 (7): 1367-1377.
11. Mabuchi S, Kawase C, Altomare D.A., et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary[J]. Clin Cancer Res, 2009, 15 (17): 5404-5413.
12. Wahid F, Shehzad A, Khan T., et al. MicroRNAs: Synthesis, mechanism, function, and recent clinical trials [J]. Biochim Biophys Acta, 2010, 1803 (11): 1231-1243.